Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02831686Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jul 2016; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02831686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831686.